Browsing by author "Smyth, Lizzy"
Now showing items 1-7 of 7
-
Adjuvant Chemotherapy Following Neoadjuvant Chemotherapy Plus Surgery for Patients With Gastroesophageal Cancer-Is There Room for Improvement?
Smyth, EC; Cunningham, D (2018-01) -
Encouraging results for PD-1 inhibition in gastric cancer.
Smyth, EC; Cunningham, D (2016-06) -
Exclusion of Gastrointestinal Cancer Patients With Prior Cancer From Clinical Trials: Is This Justified?
Smyth, EC; Tarazona, N; Peckitt, C; Armstrong, E; Mansukhani, S; et al. (2016-06)Background Strict eligibility criteria are necessary to maintain patient safety and scientific validity in clinical trials. However, this may lead to impaired generalizability of results. As survival in gastrointestinal ... -
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Smyth, EC; Verheij, M; Allum, W; Cunningham, D; Cervantes, A; et al. (2016-09) -
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.
Cunningham, D; Stenning, SP; Smyth, EC; Okines, AF; Allum, WH; et al. (2017-03)Background Peri-operative chemotherapy and surgery is a standard of care for patients with resectable oesophagogastric adenocarcinoma. Bevacizumab, a monoclonal antibody against VEGF, improves the proportion of patients ... -
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma - Authors' reply.
Smyth, EC; Allum, WH; Rowley, S; Langley, RE; Cunningham, D (2017-05) -
Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy.
Smyth, E; Zhang, S; Cunningham, D; Wotherspoon, A; Soong, R; et al. (2017-12)Purpose: Germline polymorphisms may affect chemotherapy efficacy and toxicity. We examined the effect of polymorphisms in drug metabolism and DNA repair genes on pathologic response rates, survival, and toxicity for patients ...